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Sirtuins are best known for their role in aging but also regulatemany different biological processes. A study in
this issue of Cell Metabolism (Biason-Lauber et al., 2013) now identifies a mutation in human SIRT1 causing
a familial form of autoimmune diabetes.SIRT1 is an NAD-dependent protein de-
acetylase that has garnered a reputation
for its diverse physiologic roles in metab-
olism, stress responses, tumorigenesis,
aging, and immune regulation. Sirt1 null
mice develop autoantibodies and immune
complex deposition disease resembling
systemic lupus erythematosus (Sequeira
et al., 2008). Furthermore, SIRT1 has
been implicated in T cell regulation by
affecting acetylation sites in the Foxp3
gene, a critical transcription factor
involved in the function of regulatory
T cells (Beier et al., 2012). SIRT1 has
also been found to be required for T cell
activation and for promoting clonal
anergy, thus helping to maintain T cell
tolerance (Zhang et al., 2009). In this issue
of Cell Metabolism, a study of a family
with multiple members affected by type
1 diabetes and inflammatory bowel
disease reveals a novel point mutation,
L107P, on the SIRT1 protein that appears
responsible for the autoimmune pheno-
type (Biason-Lauber et al., 2013).
Type 1 diabetes is an autoimmune
disease characterized by destruction of
pancreatic b cells and a strong genetic
component, mediated largely by MHC
class II alleles but also other monogenic
loci. The investigators of this study
suspected a novel genetic link when
they observed that, aside from the index
patient, three other family members
had juvenile-onset diabetes by the age
of 15, while another had severe ulcerative
colitis by age 16, highlighting the auto-
immune propensity of this family and
strong penetrance of the underlying
genetic condition. Indeed, all affected
individuals in this family were found to
carry a L107P mutation on SIRT1. The
mutation appears dominant, in that all
carriers developed autoimmune disease,while noncarriers did not. This newly
discovered polymorphism does not
appear to be a common cause of autoim-
mune diabetes, however. The authors
screened for the presence of the L107P
mutation in over 2,000 sporadic and
familial diabetic patients, concluding that
in fact it is an exceedingly rare polymor-
phism, absent in all subjects tested.
Moreover, this SIRT1 locus is not clearly
within the recognized type 1 diabetes
genes, and the common MHC genes
linked with type 1 diabetes were not
associated with the development of dia-
betes in this cohort, suggesting a different
mechanism of disease.
In order to characterize the role of
the L107 residue on SIRT1 function,
the authors examined SIRT1 molecular
stability, subcellular localization, interac-
tion with other proteins, and enzymatic
activity. While the L107P mutation lay
outside of the sirtuin enzymatic core,
the mutation nonetheless had a modest
effect on its deacetylase activity. Interest-
ingly, a recent report suggested that the
deacetylase activity of SIRT1 is crucially
dependent on its oligomeric state and
that aggregate formation is modulated
through phosphorylation of its Thr522
residue (Guo et al., 2012). It may therefore
be possible that the SIRT1 L107P muta-
tion, located within the N-terminal
protein-binding domain, might also affect
its oligomerization and thus enzymatic
activity.
In view of the central role of SIRT1 in
a number of biologic processes, the
findings in this family question whether
the mutation in SIRT1 affects immuno-
logic tolerance, the target tissue, or
both. Indeed, the development of T1D
and other autoimmune manifestations
is consistent with a broader effect onCell Metabolismimmune regulation that is not specific for
one particular organ. In addition, SIRT1
may be important in determining suscep-
tibility of the target tissue toward auto-
immune attack—in this case, infiltration
of the islets by immune cells, possibly
involving the local production of oxidative
species and thereby affecting the pro-
pensity of b cells to die. While overexpres-
sion of wild-type SIRT1 protects b cells
from cytokine toxicity by suppressing
the NF-kB signaling (Lee et al., 2009),
retroviral transduction of SIRT-L107P in
a b cell line, MIN6, in the present study
resulted in increased levels of inflamma-
tory mediators, including stimulated nitric
oxide synthase activity and TNF, which
have been implicated in the pathogenesis
of type 1 diabetes. Moreover, the absence
of SIRT1 appears to lead to islet vulnera-
bility, as evidenced by hastened loss of
insulin staining and presumably islet
mass in response to multiple low-dose
streptozotocin, amodel of type 1 diabetes
by inducing b cell damage with a patho-
logic immune response. Interestingly
and perhaps unsurprisingly, increased
inflammatory cytokines may also alter
insulin sensitivity. Consistent with prior
observation that increased expression
of SIRT1 and its activator resveratrol is
associated with improved insulin sensi-
tivity (Sun et al., 2007), Biason-Lauber
et al. found that SIRT-L107P increased
insulin resistance in the index patient
and in myoblasts in vitro. Therefore, it
appears that the modulation of the cyto-
kine milieu, both in the pancreas and in
muscle, is important for insulin production
and sensitivity in the context of diabetes.
This fascinating case highlights the
interactions of inflammatory mediators
and immune responses leading to the
development of autoimmunity on a17, March 5, 2013 ª2013 Elsevier Inc. 311
Figure 1. SIRT1 Regulation of Lymphocytes and b Cells in
Autoimmune Diabetes
SIRT1 as a transcriptional regulator controls multiple cellular processes
and signaling pathways that differentially affect the immune system and
pancreatic b cells. A familial mutation in the SIRT1 protein renders affected
individuals susceptible toward autoimmune diabetes and inflammatory
bowel disease, highlighting a role for SIRT1 in regulating development of
autoimmune disease.
Cell Metabolism
Previewsgenetic basis. Eisenbarth’s
original conceptualization of
the pathogenesis of type 1
diabetes in 1986 described
an initiating event that most
likely incurred inflammation,
triggering an unregulated
autoimmune response as
a major cause of b cell
destruction. Based on this
concept and the central role
that SIRT1 plays in tissue
and metabolic homeostasis
and in immune regulation, it
is conceivable that a muta-
tion in this gene that might
affect both cell damage
and immune regulation could
lead to autoimmunity (Fig-
ure 1). In considering other
potential mechanisms of
b cell death, there is emerg-
ing evidence that SIRT1 may
regulate autophagy by com-
plexing with the autophagy
machinery and by modu-
lating autophagy signaling
via mTOR and FOXO, among
other pathways (Lee et al.,
2008; Hariharan et al., 2010).An intriguing possibility, therefore, is
that pancreatic islet cells depend on
SIRT1 for autophagy flux, which is
essential for their survival (Jung et al.,
2008). Lastly, as Biason-Lauber et al.
suggest, dysregulation of cell death in
islets may result in aberrant leakage
of autoantigens, leading to activation of312 Cell Metabolism 17, March 5, 2013 ª201autoimmune effectors and amplifying
the insulitis cascade. In this regard, we
may have only glimpsed the complex
role of SIRT1 in type 1 diabetes, and
the questions raised by this study will
fuel the discovery of new SIRT1 functions
in metabolic control and autoimmune
disease pathogenesis.3 Elsevier Inc.REFERENCES
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